免疫监视在慢性粒细胞白血病无治疗缓解中的研究进展  

Progress of immunological surveillance in the treatment-free remission of chronic myelogenous leukemia

作　　者：杨岚 曹丽霞[1] 任慧娟[1] 韩艳秋[1] Yang Lan;Cao Lixia;Ren Huijuan;Han Yanqiu(Department of Hematology,Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China)

机构地区：[1]内蒙古医科大学附属医院血液科,呼和浩特010050

出　　处：《白血病．淋巴瘤》2022年第8期502-505,共4页Journal of Leukemia & Lymphoma

摘　　要：伴随着酪氨酸激酶抑制剂(TKI)的广泛应用,慢性粒细胞白血病(CML)患者获得无治疗缓解(TFR)逐步成为治疗的长期目标。疾病进展中自我更新的白血病干细胞与复发有关,对残余白血病细胞的免疫监视被认为是TFR成功的关键。近年来,在CML细胞的先天性免疫和适应性免疫方面有了众多研究突破。文章就CML患者的免疫功能和免疫标志物在TFR中的作用以及TKI组合新型免疫制剂疗法对实现更大程度TFR的研究进行阐述。With the wide application of tyrosine kinase inhibitor(TKI),to obtain treatment-free remission(TFR)has gradually become the long-term goal for patients with chronic myelogenous leukemia(CML).Self-renewing leukemia stem cells during disease progression are related with the recurrence,and surveillance of residual leukemic cells is hypothesized to be one of the critical factors in successful TFR.On the way to obtain TFR,many breakthroughs have been made in innate and adaptive immunity of CML cells.This paper reviews the immune function of CML patients,the role of the immune markers in maintaining TFR,and the exploration of TKI combined with new immunomodulator therapy to achieve a greater degree of TFR.

关 键 词：白血病 髓系 慢性 BCR-ABL阳性 免疫学监视 缓解诱导 蛋白激酶抑制剂 

分 类 号：R733.72[医药卫生—肿瘤]